Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
13.06. | Grifols' takeover bid for Biotest, accepted by 2.11% of ordinary shares with voting rights (1.05% of capital) | 38 | thecorner.eu | ||
11.06. | GRIFOLS, S.A.: Information in relation to the public delisting purchase offer for Biotest AG shares | 18 | CNMV | ||
10.06. | XL-protein GmbH: XL-protein grants worldwide license to Grifols to develop a biopharmaceutical using PASylation(R) technology | 516 | Dow Jones News | Press Release: XL-protein grants worldwide license to Grifols to develop a biopharmaceutical using PASylation(R) technology
Freising, Germany, June 10, 2025 -- XL-protein GmbH, a pioneer in... ► Artikel lesen | |
05.06. | Grifols SA - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
GRIFOLS SA ADR 1/2/EO Aktie jetzt für 0€ handeln | |||||
05.06. | GRIFOLS, S.A.: General Shareholders' Meeting 2025 | 30 | CNMV | ||
04.06. | US judge to investigate Gotham for defamation of Grifols in bearish report published in January 2024 | 24 | thecorner.eu | ||
03.06. | Mason Capital, 3.174% owner of Grifols, backs company by supporting candidate list for election of next Board | 16 | thecorner.eu | ||
30.05. | Mason Capital Management LLC: Mason Capital Management to Support Grifols Recommended Director Slate at Upcoming Ordinary General Meeting | 440 | Business Wire | Believes Board Leadership Continuity and Continued Management Focus and Execution Will Drive Long-Term Shareholder Value
Mason Capital Management LLC ("Mason"), a registered investment advisor... ► Artikel lesen | |
30.05. | Grifols lawsuit against Gotham City to proceed after New York court ruling | 8 | Seeking Alpha | ||
30.05. | US court finds enough evidence to proceed with Grifols lawsuit against Gotham City | 18 | Reuters | ||
28.05. | ADMA Biologics vs. Grifols: Which Plasma Therapy Stock Is the Better Buy? | 17 | Zacks | ||
22.05. | Grifols' rating upgraded to B2 by Moody's with positive outlook | 30 | Investing.com | ||
22.05. | Moody's stuft Grifols-Rating auf B2 mit positivem Ausblick hoch | 14 | Investing.com Deutsch | ||
13.05. | Grifols S.A. reports Q1 results | 36 | Seeking Alpha | ||
12.05. | Grifols liefert durchweg starke Ergebnisse, steigert Umsatz um 7,4%, bereinigtes EBITDA um 14,2% und verbessert Free Cash Flow um EUR 209 Mio. | 744 | news aktuell | Barcelona, Spanien (ots) - - Der Nettoumsatz erreichte 1.786 Millionen Euro (+7,4% cc1), angetrieben durch die starke Leistung von Biopharma (+6,6% cc). Auf vergleichbarer Basis (LFL2) stiegen die Nettoumsatzerlöse... ► Artikel lesen | |
12.05. | Grifols revenues rise 7.4% in Q1 after strong biopharma performance | 20 | Investing.com | ||
12.05. | Grifols SA - 6-K, Report of foreign issuer | 10 | SEC Filings | ||
12.05. | GRIFOLS, S.A.: Grifols releases its financial information for the first quarter of 2025 | 16 | CNMV | ||
07.05. | German stock market supervisor approves Grifols' takeover bid for subsidiary Biotest at €43 per share | 25 | thecorner.eu | ||
02.05. | Grifols SA - 6-K, Report of foreign issuer | 9 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
MERCK KGAA | 112,65 | +0,90 % | MilliporeSigma and "Abbott Elementary" Inspire Students' Curiosity With Hands-On STEM | NORTHAMPTON, MA / ACCESS Newswire / June 25, 2025 / Between September 2024 and April 2025, MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, teamed up with... ► Artikel lesen | |
GSK | 16,510 | +0,24 % | GSK's Benlysta Autoinjector Gets FDA Approval For Children With Active Lupus Nephritis | LONDON (dpa-AFX) - GSK plc (GSK.L) Tuesday said that the U.S. Food and Drug Administration (FDA) has approved Benlysta autoinjector for individuals aged five years and older with active lupus... ► Artikel lesen | |
VERTEX PHARMACEUTICALS | 378,70 | +0,49 % | Vertex Pharmaceuticals Incorporated (VRTX) Benefited from the Launch of its New Drug | ||
BAUSCH HEALTH | 5,500 | -0,25 % | Bausch Health Companies Inc. - 8-K, Current Report | ||
ALNYLAM PHARMACEUTICALS | 270,20 | -2,07 % | Needham erhöht Kursziel für Alnylam aufgrund optimistischer Amvuttra-Prognose | ||
NEKTAR THERAPEUTICS | 22,500 | +1,81 % | XFRA ITH0: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILNEKTAR THERAP. NEW... ► Artikel lesen | |
CANTOURAGE GROUP | 5,340 | +1,91 % | Cantourage-Aktie: Satte +20% seit der letzten SD-Analyse | Die Aktie des medizinischen Cannabisanbieters Cantourage erlebte seit unserer Analyse Mitte Mai eine Performance von rund +20%. Am Freitag notiert sie aktuell bei 6,40 €. Wie sind die weiteren Aussichten?... ► Artikel lesen | |
MEDPACE | 264,00 | -0,49 % | Barclays initiates Medpace stock coverage with equalweight rating | ||
APONTIS PHARMA | 10,800 | -0,46 % | Apontis Pharma vor Squeeze-Out zu 10,40 Euro je Aktie - HV folgt | Die Apontis Pharma AG hat mitgeteilt, dass die Zentiva AG den Vorstand zur Einberufung einer Hauptversammlung aufgefordert hat, um die Übertragung der Anteile der Minderheitsaktionäre zu beschließen.... ► Artikel lesen | |
TITAN PHARMACEUTICALS | 0,001 | -100,00 % | Titan Pharma sammelt 600.000 US-Dollar durch Privatplatzierung mit Blue Harbour | ||
SCYNEXIS | 0,631 | +4,82 % | SCYNEXIS INC - 8-K, Current Report | ||
INVENTIVA | 2,620 | +0,19 % | INVENTIVA: Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of Directors | Daix (France), New York City (New York, United States), June 10, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused... ► Artikel lesen | |
CHAMPIONS ONCOLOGY | 6,000 | -4,76 % | Champions Oncology, Inc.: Champions Oncology Obtains Radioactive Materials License to Advance Comprehensive Radiotherapeutic Studies In-House | HACKENSACK, NJ / ACCESS Newswire / April 28, 2025 / Champions Oncology (NASDAQ:CSBR), a leader in translational oncology research, has been granted a license to use radioactive materials in preclinical... ► Artikel lesen | |
GABATHER | 0,000 | 0,00 % | Gabather AB: Gabather AB and MINDIG Reveal Promising fMRI Results Demonstrating GT-002's Lasting Impact on Brain Activity | Gabather AB, a biotechnology company at the forefront of neuropsychiatric therapeutics, in collaboration with neuroimaging experts at MINDIG, announces groundbreaking results from their latest functional... ► Artikel lesen | |
BAYER | 26,975 | +2,64 % | Neuer Biotech-Boom entfacht: Evotec, BioNxt, Bayer, Novo Nordisk und Formycon vor dem nächsten Kursschub? | Die Biotechnologie-Branche erlebt derzeit eine bemerkenswerte Renaissance. Innovationen in der personalisierten Medizin, Fortschritte bei mRNA-Technologien sowie neue Therapieansätze gegen Krebs und... ► Artikel lesen |